Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome
- PMID:18226451
- DOI: 10.1016/j.neulet.2007.12.039
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome
Abstract
The most commonly used model of Down syndrome, the Ts65Dn (TS) mouse, is trisomic for most of the region of MMU16 that is homologous to HSA21. This mouse shares many phenotypic characteristics with people with Down syndrome including behavioral and cognitive alterations. The objective of this study was to analyze the ability of two drugs that improve cognition in different experimental models, the acetylcholinesterase inhibitor donepezil and the non-competitive GABA(A) antagonist pentylenetetrazole (PTZ), to improve the cognitive deficits found in TS mice. The drugs were administered p.o. to TS and CO mice for 8 weeks and a behavioral characterization was performed. Sensorimotor abilities, including vision, hearing, strength and motor coordination, as well as locomotor activity in the home cage, were not modified by any chronic treatment in TS and CO mice. TS mice showed altered equilibrium in the aluminium rod, and this effect was larger under PTZ treatment. This result may indicate a potential adverse effect of PTZ in Ts65Dn mice. Learning and memory were evaluated in TS and CO mice after both treatments in the Morris water maze. Donepezil administration did not modify learning and memory in animals of any genotype. On the other hand, PTZ administration rescued TS performance in the Morris water maze.
Similar articles
- Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome.Rueda N, Flórez J, Martínez-Cué C.Rueda N, et al.Behav Brain Res. 2008 Apr 9;188(2):355-67. doi: 10.1016/j.bbr.2007.11.020. Epub 2007 Dec 3.Behav Brain Res. 2008.PMID:18178265
- Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice.Saxena G, Singh SP, Agrawal R, Nath C.Saxena G, et al.Eur J Pharmacol. 2008 Mar 10;581(3):283-9. doi: 10.1016/j.ejphar.2007.12.009. Epub 2007 Dec 23.Eur J Pharmacol. 2008.PMID:18234183
- Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC.Belichenko PV, et al.J Comp Neurol. 2007 Oct 1;504(4):329-45. doi: 10.1002/cne.21433.J Comp Neurol. 2007.PMID:17663443
- Mouse models of cognitive disorders in trisomy 21: a review.Sérégaza Z, Roubertoux PL, Jamon M, Soumireu-Mourat B.Sérégaza Z, et al.Behav Genet. 2006 May;36(3):387-404. doi: 10.1007/s10519-006-9056-9. Epub 2006 Mar 8.Behav Genet. 2006.PMID:16523244Review.
- Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.Martínez-Cué C, Delatour B, Potier MC.Martínez-Cué C, et al.Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:218-27. doi: 10.1016/j.neubiorev.2013.12.008. Epub 2014 Jan 9.Neurosci Biobehav Rev. 2014.PMID:24412222Review.
Cited by
- Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.Gardiner KJ.Gardiner KJ.Drug Des Devel Ther. 2014 Dec 17;9:103-25. doi: 10.2147/DDDT.S51476. eCollection 2015.Drug Des Devel Ther. 2014.PMID:25552901Free PMC article.Review.
- Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.Netzer WJ, Powell C, Nong Y, Blundell J, Wong L, Duff K, Flajolet M, Greengard P.Netzer WJ, et al.PLoS One. 2010 Jun 3;5(6):e10943. doi: 10.1371/journal.pone.0010943.PLoS One. 2010.PMID:20532168Free PMC article.
- Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome.Utagawa EC, Moreno DG, Schafernak KT, Arva NC, Malek-Ahmadi MH, Mufson EJ, Perez SE.Utagawa EC, et al.Acta Neuropathol Commun. 2022 Jun 8;10(1):86. doi: 10.1186/s40478-022-01385-w.Acta Neuropathol Commun. 2022.PMID:35676735Free PMC article.
- Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.Ruparelia A, Wiseman F, Sheppard O, Tybulewicz VL, Fisher EM.Ruparelia A, et al.J Biomed Res. 2010 Mar;24(2):87-99. doi: 10.1016/S1674-8301(10)60016-4.J Biomed Res. 2010.PMID:23554618Free PMC article.
- Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome.Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos Á, Flórez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG, Hernández MC.Martínez-Cué C, et al.J Neurosci. 2013 Feb 27;33(9):3953-66. doi: 10.1523/JNEUROSCI.1203-12.2013.J Neurosci. 2013.PMID:23447605Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases